United Kingdom (UK)
Recombinant monoclonal antibody to Envelopment polyprotein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the B cell culture R12.
UniProt Accession Number of Target Protein: P03518
Alternative Name(s) of Target: GP; M polyprotein
Immunogen: This original antibody was raised by screening B cells from a Rift Valley fever patient and sequencing the VH and VL antibody regions.
Specificity: This antibody is specific for the DI domain, including residues K164, H166, 173-TQEDA-177, K180, P273, K274, 291-SLK-293, and K395 of rift valley fever glycoprotein N
Application Notes: The original version of this antibody was used for an ELISA on rift valley fever Gn and Gc. Further this antibody was used for flow cytometry on HEK293T cells transiently transfected with plasmids of pEGFP-M, pEGFP-Gn, pEGFP-Gc or pEGFP-Gn mutants. This antibody was used for a blocking assay, the rift valley virus was preincubated with this antibody and the mixture was then added to Vero cells. This antibody was used for a western blot on its linear epitope. This antibody was used for surface plasmon resonance on rift valley fever Gn and Gc. A neutralization assay with this antibody was performed using flow cytometry on rift valley virus and Vero cells. The antibodies were added pre-infection. This antibody was used for an in vivo assay. Mice were infected with the rift valley virus. Then post infection they were given this antibody. This lead to all of the mice surviving, where the control group all died. Finally the structure of this antibody was determined using x-ray crystallography (Wang et al., 2019; PMID:30936489).
Antibody first published in:
Wang et al. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus Nat Microbiol. 2019 Jul;4(7):1231-1241. PMID:30936489
Note on publication:
The original paper reports the isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc.